- Top Page
- Profile
last modified：2025/03/29
Assistant Professor Fukuda, Koji
Faculty, Affiliation
Cancer Research Institute
College and School Educational Field
Laboratory
Academic Background
Career
Kanazawa university cancer institute(2017/11/01-)
South Illinois University school of medicine(2010/07/01-2012/07/31)
Year & Month of Birth
Academic Society
Award
Specialities
Speciality Keywords
Research Themes
Books
Papers
- GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Kenji Kita, Azusa Tanimoto, Akihiro Nishiyama, Seiji Yano Cancer Science 111 7 2374-2384 2020
- Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, Satouchi M, Yamashita K, Ohtsubo K, Nanjo S, Kumagai T, Katayama R, Nishio M, Zheng MM, Wu YL, Nishihara H, Yamamoto T, Nakada M, Yano S. J Thorac Oncl 2020/01/21
- Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Cancer Science 111 2 561-570 2020/02/01
- Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, Yano S. Mol Cancer Ther 18 5 947-956 2019/05/01
- Aberrant Methylation of Tumor Suppressive miRNAs in Bile from Patients With Pancreaticobiliary Diseases. Ohtsubo K, Miyake K, Arai S, Fukuda K, Yanagimura N, Suzuki C, Otani S, Adachi Y, Tanimoto A, Nishiyama A, Yamashita K, Takeuchi S, Notohara K, Yoshimura K, Yano S Anticancer Res 39 10 5449-59 2019/10/01
- Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance. Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S. Cancer Science 110 10 3215-3224 2019/10/01
- Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa Y, Baba S, Takeuchi K, Horiike A, Yanagitani N, Nishio M, Yano S. Cancer Research 2019/02/08
- Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Arasada RR, Shilo K, Yamada T, Zhang J, Yano S, Ghanem R, Wang W, Takeuchi S, Fukuda K, Katakami N, Tomii K, Ogushi F, Nishioka Y, Talabere T, Misra S, Duan W, Fadda P, Rahman MA, Nana-Sinkam P, Evans J, Amann J, Tchekneva EE, Dikov MM, Carbone DP. Nature Communications 2018/08/10
- Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model. Clinical Cancer Research 2018/02/20
- In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs. Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S Cancer Medicine 2017/11/01
- In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET Sachiko Arai , Kenji Kita , Azusa Tanimoto , Shinji Takeuchi , Koji Fukuda , Hiroshi Sato, Seiji Yano Oncotarget in publish 2017/03/19
- Podoplanin promotes progression of malignant pleural mesothelioma by regulating motility and focus formation. Takeuchi S, Fukuda K, Yamada T, Arai S, Takagi S, Ishii GI, Ochiai A, Iwakiri S, Itoi K, Uehara H, Nishihara H, Fujita N, Yano S. Cancer Science [Epub ahead of print] 2017/02/09
- Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism-Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer. Tanimoto A, Takeuchi S, Arai S, Fukuda K, Yamada T, Roca X, Ong ST, Yano S Clinical cancer research 2016/12/16
- Organ-specific efficacy of HSP90 inhibitor in multiple-organ metastasis model of chemorefractory small cell lung cancer. Takeuchi S, Fukuda K, Arai S, Nanjo S, Kita K, Yamada T, Hara E, Nishihara H, Uehara H, Yano S. International Journal of cancer 138 5 1281-9 2016
- Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S. Cancer Science 108 1 53-60 2017/01/01
Conference Presentations
- Epithelial-mesenchymal transition as an idependent mechanism of ALK inhibitor resistance in EML4-ALK lung cancer(conference：The 77th Annual Meeting of the Japanese Cancer Association)(2018/09/27)
- Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.(conference：IASLC 2019 World Conference on Lung Cancer.)(2019/09)
- Epithelial-To-Mesenchymal Transition Is a Mechanisms of ALK inhibitor Resistance in Lung Cancer Independent of ALK Mutation Status (conference：IASLC 2019 World Conference on Lung Cancer)(2019/09/07)
- Epithelial-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status (2019/06/12)
- Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention.(conference：Fifth AACR-IASLC International Joint Conference)(2018/01/08)
- HDAC inhibition overcomes crizotinib-resistance by mesenchymal-epithelial transition (MET) in EML4-ALK lung cancer cells (2016/10/06)
- HDAC inhibition overcomes crizotinib-resistance by inducing mesenchymal-epithelial reverting transition (MERT) via miR-200c up-regulation in EML4-ALK lung cancer cells.(conference：Tenth AACR-JCA joint conference)(2016)
Others
Arts and Fieldwork
Patent
Theme to the desired joint research
Grant-in-Aid for Scientific Research
○「KRAS変異肺癌におけるDNA損傷応答経路を標的とした新規治療法の開発」(2024-2026)
○「EGFR肺癌の髄膜癌腫症におけるEGFR-TKI耐性克服治療の開発」(2021-2023)
○「miR-200sを標的とした肺癌のEMTに起因するTKI耐性克服治療の開発」(2018-2020)
○「ALK肺癌のEMTに起因するALK-TKI耐性克服治療の開発」(2016-)